Lung Cancer
Conditions
Brief summary
The next generation of personalized medical treatment according to the type of personal genetic information are evolving rapidly. The genome analysis needs systematic infra and database based on personal genetic information Therefore, a big data of genome-clinical information is important.
Detailed description
To determine the feasibility of the use of tumor's molecular profiling and targeted therapies in the treatment of advanced cancer and to determine the clinical outcome(PFS, duration of response and overall survival) of patients with advanced cancer, the investigators are going to take a fresh tissue of patients and process molecular profiling.
Interventions
GENETICGenetic test
Next-generation sequencing (AmpliSeq) & fusion analysis
Sponsors
Samsung Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* metastatic, histologically confirmed NSCLC, head & Neck Cancer, Esophageal cancer
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the spectrum of targetable genetic mutation in evaluated cancer specimens (for example, % of EGFR T790M mutation, BRAF mutation, or ALK mutation) | 3 years | The pattern of the tumor's molecular profiling in advanced thoracic (lung, esophagus, or tthymic) cancer |
Countries
South Korea
Contacts
Primary ContactKeunchil Park
Outcome results
None listed